» Articles » PMID: 31913016

Cell-Membrane-Based Biomimetic Systems with Bioorthogonal Functionalities

Overview
Journal Acc Chem Res
Specialty Chemistry
Date 2020 Jan 9
PMID 31913016
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

During the past decade, there was a fast development of cell-based biomimetic systems, which are commonly derived from cell membranes, cell vesicles, or living cells. Such systems have unique and inherent bioinspired features originating from their parent biological systems. In particular, they are capable of (i) prolonging blood circulation time, (ii) avoiding immune response, (iii) targeting desired sites, (iv) providing antigens in cancer immunotherapy, and (v) loading and delivering therapeutic or imaging agents. Thus, these biomimetic systems are promising as prevention, detection, diagnosis, and therapeutic modalities. Though promising, these cell-based biomimetic systems are still far from wide application. One of the important reasons is the inevitable difficulty in their further efficient and precise functionalization. Bioorthogonal chemistry results in fast, specific, and high-yielding ligation under mild biological conditions without interactions with surrounding biomolecules or disturbance of the whole biosystem. Moreover, bioorthogonal chemical groups can be introduced into cells, especially into cell membranes, through cellular biosynthesis and metabolic incorporation. Hence, a specific and reliable approach for cell membrane functionalization based on bioorthogonal chemistry has been opportunely put forward and rapidly developed. In this Account, we summarize our recent research on the development of biomimetic systems by integrating bioorthogonal chemistry with biomimetic approaches. First, an exogenously supplied unnatural biosynthetic precursor (e.g., an amino acid or lipid) bearing a bioorthogonal group (e.g., azide or tetrazine) is fed to living cells and metabolically incorporated into targeted biomolecules via cellular biosynthesis regardless of the cell phenotype. After that, different functional molecules can be anchored to the cell membranes through bioorthogonal chemical reactions by using previously inserted "artificial chemical groups". Therefore, this safe, direct, and long-term engineering strategy endows the natural cell-based biomimetic systems with additional chemical or biological performances such as labeling, targeting, imaging, and therapeutic capabilities, providing a powerful tool for the construction of biomimetic systems. Interestingly, we have successfully fabricated various biomimetic systems and applied them in (1) living virus labeling, (2) targeting delivery and enrichment of drugs/imaging agents, and (3) disease theranostics. This Account may contribute to the further development of biomimetic systems and facilitate their biological and biomedical applications in the future. With this Account we also hope to attract more cooperative interests from different fields such as chemistry, materials science, biology, pharmacy, and medicine in promoting lab-to-clinic translation of cell-based biomimetic systems combined with these two cutting-edge techniques.

Citing Articles

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve.

Niazi S Biomedicines. 2025; 12(12.

PMID: 39767824 PMC: 11673353. DOI: 10.3390/biomedicines12122918.


Translocation of TiCO MXene monolayer through the cell membranes.

Ahmadi H, Abdolvahab R, Esmaeilzadeh M RSC Adv. 2024; 14(43):31577-31586.

PMID: 39372055 PMC: 11451337. DOI: 10.1039/d4ra05821f.


Immune-defensive microspheres promote regeneration of the nucleus pulposus by targeted entrapment of the inflammatory cascade during intervertebral disc degeneration.

Zhou L, Cai F, Zhu H, Xu Y, Tang J, Wang W Bioact Mater. 2024; 37:132-152.

PMID: 38549774 PMC: 10972768. DOI: 10.1016/j.bioactmat.2024.03.020.


Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems.

Wang Z, Wang X, Xu W, Li Y, Lai R, Qiu X Pharmaceutics. 2023; 15(11).

PMID: 38004601 PMC: 10674763. DOI: 10.3390/pharmaceutics15112623.


Lipid-Centric Design of Plasma Membrane-Mimicking Nanocarriers for Targeted Chemotherapeutic Delivery.

Ning D, Wang Z, Wang L, Tian Y, Jing F, Jiang L Adv Mater. 2023; 36(2):e2306808.

PMID: 37732588 PMC: 10898849. DOI: 10.1002/adma.202306808.